Document type: Statistical Analysis Plan Official Title: A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas NCT Number: NCT02261714 Document date: 02/05/18 Syne qua non study no: TAX12001 Targovax ASA study no: CT TG01 -01 Date: 02MAY2018 Page 1 of 21 Version: Amendment 1.0 Final 1.0 ST/form/010/10 A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas Targov ax ASA Study No: CT TG01 -01 Syne qua non Ltd Study No: TAX12001 Statistical Analysis Plan Version: Amendment 1.0 Final 1.0 Date: 02 May 2018 For Syne qua non Ltd – Lead Statistician For Targovax AS A If signing manually, please include : Signature + Date + Full Name + Position Syne qua non study no: TAX12001 Targovax ASA study no: CT TG01 -01 Date: 02MAY2018 Page 2 of 21 Version: Amendment 1.0 Final 1.0 ST/form/010/10 Contents ABBREVIATIONS ................................................................................................................................... 3 1 INTRODUCTION .............................................................................................................................